A Phase 3 interventional study of Placebo and Epoetin alfa in Myelodysplastic Syndromes and Anemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-05.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes — 2 open to participants now, 4 under way, 2 of them phase 3. Epoetin Alfa · Myelodysplastic Syndromes.
Among the 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes, this one is one of 2 that started in 2008, is one of 5 in phase 3, and was the 5th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →2 of the 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes are open now, in 5 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Groupe Francophone des Myelodysplasies · Sites in France, Italy
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 5
First in 1998; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 124 across the 9 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
21 studies in Myelodysplastic Syndromes by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 16 finished, 6 (38%) have results posted.
Among the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2008, is one of 3 in phase 3, and was the 6th registered.
Johnson & Johnson’s Myelodysplastic Syndromes studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing Epoetin Alfa in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 21 in Myelodysplastic Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS). Myelodysplastic syndromes are a group of disorders characterized by progressive bone marrow failure and an increased risk of development of leukemia.
This is a randomized (patients are assigned by chance to a treatment group), double-blind (neither the patient or the physician know which treatment is being received by the patient), placebo-controlled, multicenter study of epoetin alfa in anemic patients who are diagnosed with myelodysplastic syndromes (MDS) according to protocol-specified criteria. Patients meeting entry criteria for the study will be randomly assigned to receive epoetin alfa 40,000 IU or 80,000 IU or a matching volume of placebo administered by subcutaneous (under the skin) injection once every week. Doses of study drug will be withheld, decreased, or increased on the basis of weekly hemoglobin concentrations monitored in patients and predefined dose adjustment guidelines. An Independent Data Monitoring Committee (IDMC) will periodically review study data and for the assessment of disease progression, an independent central reviewer will review bone marrow specimens and peripheral blood counts. Safety will be monitored throughout the study at predetermined intervals and as clinically indicated by physical examination, laboratory tests and evaluation of adverse events. Patients in the Treatment Phase will be randomly assigned to receive once weekly epoetin alfa subcutaneously (SC) at a dose of 40,000 IU (1 mL) or 80,000 IU (2ML) or matching volume of placebo (1 mL or 2 mL) once every week for 48 weeks. Patients may continue to receive double-blinded treatment after 48-weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
Drug: Epoetin alfa
Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
Drug: Epoetin alfa
Placebo Matching volume 1 mL for 48 weeks
Drug: Placebo
Placebo Matching volume 2 mLfor 48 weeks
Drug: Placebo
Matching volume 2 mLfor 48 weeks
40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
Matching volume 1 mL for 48 weeks
80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
Red Blood Cell (RBC) Transfusion
Incidence of participants who received at least 1 Red Blood Cell (RBC) transfusion during the study (from randomization through the end of study)
Time frame: Approximately 48 weeks
RBC Transfusion From Day 29 Through the End of Study
incidence of participants who received at least 1 RBC transfusion from Day 29 through the end of study (approximately 48 weeks).
Time frame: Day 29 through the end of study (approximately 48 weeks)
Transfusion Dependent
Participants who were transfusion-dependent were those who received 4 or more RBC units during a consecutive 8-week period.
Time frame: Approximately 48 weeks
| Milestone | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU |
|---|---|---|---|
| Started | 8 | 8 | 9 |
| Completed | 1 | 0 | 1 |
| Not completed | 7 | 8 | 8 |
| Withdrew: Study closed prematurely | 5 | 6 | 8 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 |
Incidence of participants who received at least 1 Red Blood Cell (RBC) transfusion during the study (from randomization through the end of study)
| participants | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU |
|---|---|---|---|
| Red Blood Cell (RBC) Transfusion | 5 | 3 | 1 |
incidence of participants who received at least 1 RBC transfusion from Day 29 through the end of study (approximately 48 weeks).
| participants | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU |
|---|---|---|---|
| RBC Transfusion From Day 29 Through the End of Study | 4 | 2 | 1 |
Participants who were transfusion-dependent were those who received 4 or more RBC units during a consecutive 8-week period.
| participants | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU |
|---|---|---|---|
| Transfusion Dependent | 2 | 2 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/8 (25%) | 7/8 (87.5%) |
| Epoetin Alfa 40000 IU | — | 2/8 (25%) | 4/8 (50%) |
| Epoetin Alfa 80000 IU | — | 4/9 (44.4%) | 6/9 (66.7%) |
| Event | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU |
|---|---|---|---|
| Aplasia Pure Red CellBlood and lymphatic system disorders | 1/8 | 0/8 | 0/9 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/8 | 0/8 | 0/9 |
| Vision BlurredEye disorders | 0/8 | 1/8 | 0/9 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/8 | 1/8 | 0/9 |
| AstheniaGeneral disorders | 0/8 | 1/8 | 0/9 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/8 | 1/8 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 0/8 | 1/9 |
| SplenomegalyBlood and lymphatic system disorders | 0/8 | 0/8 | 1/9 |
| Humerus FractureInjury, poisoning and procedural complications | 0/8 | 0/8 | 1/9 |
| Wrist FractureInjury, poisoning and procedural complications | 0/8 | 0/8 | 1/9 |
| Event | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU |
|---|---|---|---|
| FatigueGeneral disorders | 2/8 | 2/8 | 1/9 |
| AnaemiaBlood and lymphatic system disorders | 2/8 | 0/8 | 0/9 |
| DizzinessNervous system disorders | 2/8 | 0/8 | 1/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/8 | 1/8 | 1/9 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/8 | 2/8 | 1/9 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 | 2/9 |
| AstheniaGeneral disorders | 1/8 | 0/8 | 2/9 |
| Abdominal DiscomfortGastrointestinal disorders | 1/8 | 0/8 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 1/8 | 0/9 |
| HaematocheziaGastrointestinal disorders | 1/8 | 0/8 | 0/9 |
| Age, Categorical(Participants) | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 2 | 4 |
| >=65 years | 7 | 7 | 7 | 21 |
| Age Continuous(years) | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU | Total |
|---|---|---|---|---|
| Mean | 73 ± 10.52 | 77.3 ± 9.78 | 67.7 ± 9.89 | 72.4 ± 10.44 |
| Sex: Female, Male(Participants) | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU | Total |
|---|---|---|---|---|
| Female | 2 | 3 | 7 | 12 |
| Male | 6 | 5 | 2 | 13 |
| Region of Enrollment(participants) | Placebo | Epoetin Alfa 40000 IU | Epoetin Alfa 80000 IU | Total |
|---|---|---|---|---|
| CANADA | 1 | 0 | 0 | 1 |
| ITALY | 0 | 1 | 0 | 1 |
| RUSSIA | 2 | 0 | 4 | 6 |
| USA | 5 | 7 | 5 | 17 |
No study locations are listed for this record.
The record gives a start of Jun 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →